Summary statistics - quantitative results

EQA round: BIL1/24 - Bilirubin Neonatal

Deadline: 16.2.2024

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value
SD = standard deviation	CVP = consensus of all participants
CV = coefficient of variation	CVPG = consensus of the participants' groups
N_{tot} = total number of the results	U_{AV} = expanded uncertainty of the assigned value (k = 2)
N_{out} = number of the results removed before calculation	

D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability						N_{eva}	N_{suc}	S_{rel} [%]
								AV	U_{AV}	D_{max}	LL	UL			
(215) Bilirubin total	[µmol/L]				18								17	17	100
Sample A		204	9,3	4,5	18								17	17	100
(2) DCA, DPD		203	11	5,4	14	0	CVP	202	3	18%	165	239	14		
Other					4	0							3		
2x 1, 1x 5, 1x 7/179															
Sample B		319	13	4,1	18								17	17	100
(2) DCA, DPD		317	14	4,5	14	0	CVP	315	4,5	18%	258	372	14		
Other					4	0							3		
2x 1, 1x 5, 1x 7/179															
(216) Bilirubin direct	[µmol/L]				12								9	9	100
Sample A		44,1	9,1	21	12								9	9	100
(2) DCA, DPD; (58) Beckman Coulter (AU)		48,2	2,1	4,5	5	0	CVPG	48,8	1,8	18%	40	57,6	5		
Other					7	0							4		
2x 0/0, 1x 1/58, 1x 2/1, 2x 2/60, 1x 7/179															
Sample B		61	10	17	12								9	9	100
(2) DCA, DPD; (58) Beckman Coulter (AU)		66,6	2,8	4,2	5	0	CVPG	67,4	1,9	18%	55,2	79,6	5		
Other					7	0							4		
2x 0/0, 1x 1/58, 1x 2/1, 2x 2/60, 1x 7/179															